A61P 3/10
For hyperglycaemia
Official title: for hyperglycaemia, e.g. antidiabetics
A61P3/10 (For hyperglycaemia) appears on 27,453 US grants and 43,384 published applications in this corpus.
Search patents in A61P- Granted patents
- 27,453
- Published applications
- 43,384
- Assignees
- 8,735
- Inventors
- 57,122
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 3 | 0 |
| 1978 | 5 | 0 |
| 1979 | 7 | 0 |
| 1980 | 11 | 0 |
| 1981 | 17 | 0 |
| 1982 | 16 | 0 |
| 1983 | 9 | 0 |
| 1984 | 15 | 0 |
| 1985 | 15 | 0 |
| 1986 | 22 | 0 |
| 1987 | 16 | 0 |
| 1988 | 19 | 0 |
| 1989 | 16 | 0 |
| 1990 | 21 | 0 |
| 1991 | 26 | 0 |
| 1992 | 30 | 0 |
| 1993 | 30 | 0 |
| 1994 | 38 | 0 |
| 1995 | 45 | 0 |
| 1996 | 71 | 0 |
| 1997 | 106 | 0 |
| 1998 | 178 | 0 |
| 1999 | 199 | 0 |
| 2000 | 270 | 0 |
| 2001 | 387 | 160 |
| 2002 | 507 | 771 |
| 2003 | 566 | 1386 |
| 2004 | 487 | 1824 |
| 2005 | 540 | 1869 |
| 2006 | 756 | 1932 |
| 2007 | 817 | 2088 |
| 2008 | 920 | 2358 |
| 2009 | 1090 | 2724 |
| 2010 | 1498 | 3163 |
| 2011 | 1582 | 2943 |
| 2012 | 1779 | 2566 |
| 2013 | 1974 | 2156 |
| 2014 | 1961 | 2267 |
| 2015 | 1692 | 1991 |
| 2016 | 1392 | 1913 |
| 2017 | 1457 | 1722 |
| 2018 | 1228 | 1515 |
| 2019 | 1135 | 1543 |
| 2020 | 1076 | 1305 |
| 2021 | 884 | 1133 |
| 2022 | 656 | 1043 |
| 2023 | 555 | 894 |
| 2024 | 520 | 862 |
| 2025 | 509 | 764 |
| 2026 | 299 | 492 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Benzimidazole compound for the treatment of metabolic disorders29 Sep 2026US 12,746,227 B2Ache Laboratorios Farmaceuticos S/A
- Dynamic-covalent hydrogels with glucose-specific and glucose-responsive diboronate crosslinking29 Sep 2026US 12,746,277 B2University of Notre Dame du Lac
- Composition for preventing, ameliorating, or treating metabolic syndromes including obesity, diabetes, hyperlipidemia, and fatty liver22 Sep 2026US 12,741,007 B2Nutracore Co., Ltd.
- Insulin-Fc fusion proteins and methods of use to treat cancer22 Sep 2026US 12,742,000 B2Akston Biosciences Corporation
- Method for treating diabetes by using Antrodia camphorata compound15 Sep 2026US 12,734,148 B2Lantyng Biotechnology Corp.
- Fgf21 compound / glp-1r agonist combinations with optimized activity ratio8 Oct 2026US 2026/0306587 A1Sanofi
- Antidiabetic pharmaceutical composition1 Oct 2026US 2026/0294823 A1Imam Abdulrahman Bin Faisal University
- Pharmaceuticl compositions comprising bile acid compounds for oral delivery of therapeutic peptides1 Oct 2026US 2026/0294936 A1Waterstone Pharmaceuticals(Wuhan) Co., Ltd.
- Uses of super-oxide dismutase supplements1 Oct 2026US 2026/0295019 A1
- Glucagon-like peptide-1 receptor agonist variants and methods thereof1 Oct 2026US 2026/0295054 A1
Most cited
By later US patents
- Humanized immunoglobulins2,884US 5,585,089 AProtein Design Labs, Inc. · 1996
- Humanized immunoglobulins2,259US 5,530,101 AProtein Design Labs, Inc. · 1996
- Humanized immunoglobulins2,030US 5,693,762 AProtein Design Labs, Inc. · 1997
- Diabetes management system1,937US 6,544,212 B2Roche Diagnostics GmbH · 2003
- Modular infusion device and method1,554US 6,749,587 B2Insulet Corporation · 2004